<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Medical Physics - Latest articles</title>
		<link>http://www.biomedcentral.com/bmcmedphys/</link>
		<description>The latest articles from BMC Medical Physics (ISSN 1756-6649) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/8/3"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/8/2"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/8/1"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/7/5"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/7/4"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/7/3"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/7/2"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/7/1"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/6/5"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/6/4"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.biomedcentral.com/1756-6649/8/3">
            
            <title>NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)</title>
			<description>Background:
Surgical resection is the preferred treatment of potentially curable esophageal cancer. To improve long term patient outcome, many institutes apply neoadjuvant chemoradiotherapy. In a large proportion of patients no response to chemoradiotherapy is achieved. These patients suffer from toxic and ineffective neoadjuvant treatment, while appropriate surgical therapy is delayed. For this reason a diagnostic test that allows for accurate prediction of tumor response early during chemoradiotherapy is of crucial importance. CT-scan and endoscopic ultrasound have limited accuracy in predicting histopathologic tumor response. Data suggest that metabolic changes in tumor tissue as measured by FDG-PET predict response better. This study aims to compare FDG-PET and CT-scan for the early prediction of non-response to preoperative chemoradiotherapy in patients with potentially curable esophageal cancer.
Methods/design: Prognostic accuracy study, embedded in a randomized multicenter Dutch trial comparing neoadjuvant chemoradiotherapy for 5 weeks followed by surgery versus surgery alone for esophageal cancer. This prognostic accuracy study is performed only in the neoadjuvant arm of the randomized trial. In 6 centers, 150 consecutive patients will be included over a 3 year period.  FDG-PET and CT-scan will be performed before and 2 weeks after the start of the chemoradiotherapy. All patients complete the 5 weeks regimen of neoadjuvant chemoradiotherapy, regardless the test results. Pathological examination of the surgical resection specimen will be used as reference standard. Responders are defined as patients with &lt; 10% viable residual tumor cells (Mandard-score).
Difference in accuracy (area under ROC curve) and negative predictive value between FDG-PET and CT-scan are primary endpoints.  Furthermore, an economic evaluation will be performed, comparing survival and costs associated with the use of FDG-PET (or CT-scan) to predict tumor response with survival and costs of neoadjuvant chemoradiotherapy without prediction of response (reference strategy).DiscussionThe NEOPEC-trial could be the first sufficiently powered study that helps justify implementation of FDG-PET for response-monitoring in patients with esophageal cancer in clinical practice.
Trial registration: ISRCTN45750457</description>
			<link>http://www.biomedcentral.com/1756-6649/8/3</link>
			
			 	<dc:creator>Mark van Heijl, Jikke MT Omloo, Mark I van Berge Henegouwen, Olivier RC Busch, Hugo W Tilanus, Patrick MM Bossuyt, Otto S Hoekstra, Jaap Stoker, Maarten CCM Hulshof and Ate van der Gaast</dc:creator>
			
			<dc:source>BMC Medical Physics 2008, 8:3</dc:source>
			<dc:date>2008-07-31</dc:date>
			<dc:identifier>doi:10.1186/1756-6649-8-3</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-31</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1756-6649/8/2">
            
            <title>A computerized Infusion Pump for control of tissue tracer concentration during Positron Emission Tomography in vivo Pharmacokinetic/Pharmacodynamic measurements</title>
			<description>Background:
A computer controlled infusion pump (UIPump) for regulation of target tissue concentration of radioactive compounds was developed for use in biological research and tracer development for PET.
Methods:
Based on observed tissue or plasma kinetics after a bolus injection of the tracer an algorithm calculates the infusion needed to obtain a specified target kinetic curve. A computer feeds this infusion scheme into an infusion pump connected to an animal via a venous catheter. The concept was validated using [11C]Flumazenil administrated to Sprague-Dawley rats where the whole brain distribution and kinetic of the tracer was measured over time using a microPET-scanner. The accuracy and precision of the system was assessed by producing steady-state levels of the tracer and by mimicking kinetics after oral administration.
Results:
Various kinetic profiles could be generated, including rapid achievement of constant levels, or step-wise increased levels. The resulting tissue curves had low deviation from the target curves according to the specified criteria: AUC (%): 4.2 &#177; 2.8, Maximal deviation (%): 13.6 &#177; 5.0 and R2: 0.95 &#177; 0.02.
Conclusion:
The UIPump-system is suitable for use in PET-research for assessment of PK/PD properties by simulation of different tracer tissue kinetics in vivo.</description>
			<link>http://www.biomedcentral.com/1756-6649/8/2</link>
			
			 	<dc:creator>Olof Eriksson, Andreas Wallberg, Stina Syv&#228;nen, Raymond Josephsson, Bengt L&#229;ngstr&#246;m and Mats Bergstr&#246;m</dc:creator>
			
			<dc:source>BMC Medical Physics 2008, 8:2</dc:source>
			<dc:date>2008-05-30</dc:date>
			<dc:identifier>doi:10.1186/1756-6649-8-2</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1756-6649/8/1">
            
            <title>Perfusion scanning using 99mTc-HMPAO detects early cerebrovascular changes in the diabetic rat</title>
			<description>Background:
99mTc-HMPAO is a well-established isotope useful in the detection of regional cerebral blood flow. Diabetes gives rise to arterial atherosclerotic changes that can lead to significant end organ dysfunction, prominently affecting perfusion to the heart, kidneys, eyes and brain. In the current study, we investigated the role of 99mTc-HMPAO cerebral perfusion scans in detecting early vascular changes in the diabetic brain.
Methods:
Cerebral perfusion studies were performed on both control and streptozotocin-(STZ) induced diabetic male Wistar rats. Rat brain imaging using a gamma camera was performed for each group 0.5, 2, 4, and 24 hours post 99mTc-HMPAO injection. Data processing for each cerebral perfusion scan was performed by drawing a region of interest (ROI) circumferentially around the brain (B). Background (BKG) due to signal from the soft tissue of each rat was subtracted. Brain 99mTc-HMPAO uptake minus background counts (net brain counts; NBC) were then compared between the two groups.
Results:
The NBC (mean &#177; SD) for the STZ group were statistically significantly higher (p = 0.0004) than those of the control group at each of the time points studied.
Conclusion:
99mTc-HMPAO brain scan may be useful in the detection of early atherosclerotic changes in the diabetic rat brain.</description>
			<link>http://www.biomedcentral.com/1756-6649/8/1</link>
			
			 	<dc:creator>Fatma J Al-Saeedi</dc:creator>
			
			<dc:source>BMC Medical Physics 2008, 8:1</dc:source>
			<dc:date>2008-03-13</dc:date>
			<dc:identifier>doi:10.1186/1756-6649-8-1</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1756-6649/7/5">
            
            <title>Computer-assisted lateralization of unilateral temporal lobe epilepsy using Z-score parametric F-18 FDG PET images</title>
			<description>Background:
To evaluate the use of unbiased computer-assisted lateralization of temporal lobe epilepsy (TLE) by z-score parametric PET imaging (ZPET).
Methods:
38 patients with histologically proven unilateral TLE due to pure hippocampal sclerosis, referred for pre-surgical PET evaluation of intractable seizure over a 5-year period, were included. The F-18 FDG images were oriented along temporal long axis and then transformed into ZPET images on a voxel by voxel basis. Multiple regions of interests (21 in total) were placed on cortical, subcortical and cerebellar structures on twenty-eight out of 38 patients with totally seizure-free (class I) outcome. Paired t-tests with Bonferroni correction were used to determine the location of the most asymmetric regions as variables for subsequent discriminant analysis of the entire group of the patients.
Results:
The computer program identified the anterior half of the temporal lobe (p &lt; 0.0005) and thalami (p = 0.021) as the most asymmetric regions in TLE patients with Class I outcome. Discriminant analysis using z-scores from a total of 8 ROIs (in 4 pairs) on these structures correctly lateralized thirty-seven out of 38 (97%) patients (sensitivity = 94%; specificity = 100%). The only false localization came from a patient with equivocal z-scores on the temporal lobes and this patient turned out to have poor outcome.
Conclusion:
The computer-assisted lateralization of TLE using ZPET provides an accurate, fast and objective way of seizure evaluation.</description>
			<link>http://www.biomedcentral.com/1756-6649/7/5</link>
			
			 	<dc:creator>Ching-yee Oliver Wong, James Gannon, Jeffrey Bong, Christiana O Wong and Gopal B Saha</dc:creator>
			
			<dc:source>BMC Medical Physics 2007, 7:5</dc:source>
			<dc:date>2007-11-02</dc:date>
			<dc:identifier>doi:10.1186/1471-2385-7-5</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-02</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1756-6649/7/4">
            
            <title>Comparison of 2D, 3D high dose and 3D low dose gated myocardial 82Rb PET imaging</title>
			<description>Background:
We compared 2D, 3D high dose (HD) and 3D low dose (LD) gated myocardial Rb-82 PET imaging in 16 normal human studies. The main goal in the paper is to evaluate whether the images obtained by a 3D LD studies are still of comparable clinical quality to the images obtained with the 2D HD or 3D HD studies.
Methods:
All 2D and 3D HD studies were performed with 2220 MBq of Rb-82. The 3D LD were performed with 740 MBq of Rb-82. A GE Advance PET system was used for acquisition. Polar maps were created and used to calculate noise among (NAS) and within (NWS) the segments in the noise analysis. In addition, the contrast between left ventricular (LV) wall and LV cavity was also analysed. For 13 subjects, ejection fraction (EF) on 2D and 3D studies was calculated using QGS program.
Results:
For the H20 reconstruction filter, the mean contrast in mid-ventricular short-axis slice was 0.33 &#177; 0.06 for 2D studies. The same contrast for the 3D HD studies was 0.38 &#177; 0.07 and for 3D LD, it was 0.34 &#177; 0.08. For the 6 volunteers where 3D HD was used, NAS was 3.64*10-4 and NWS was 1.79*10-2 for 2D studies, and NAS was 3.70*10-4 and NWS was 1.85*10-2 for 3D HD studies, respectively. For the other 10 volunteers where 3D LD was used, NAS was 3.85*10-4 and NWS was 1.82*10-2 for the 2D studies, and NAS was 5.58*10-4 and NWS was 1.91*10-2 for the 3D LD studies, respectively. For the sharper H13 filter, the data followed the same pattern, with slightly higher values of contrast and noise. EF values in 2D and 3D were close. The Pearson's correlation coefficient was 0.90. The average difference from 13 subjects was 8.3%.
Conclusion:
2D and 3D HD gating Rb-82 PET cardiac studies have similar contrast, ejection fractions and noise levels. 3D LD gating imaging, gave comparable results in terms of contrast, EF and noise to either 2D or 3D HD gating PET imaging. 3D LD PET gated imaging can make Rb-82 PET cardiac imaging more affordable with significantly less radiation exposure to the patients.</description>
			<link>http://www.biomedcentral.com/1756-6649/7/4</link>
			
			 	<dc:creator>Karin Kne&#353;aurek, Josef Machac and Jong Ho Kim</dc:creator>
			
			<dc:source>BMC Medical Physics 2007, 7:4</dc:source>
			<dc:date>2007-10-22</dc:date>
			<dc:identifier>doi:10.1186/1471-2385-7-4</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-10-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1756-6649/7/3">
            
            <title>Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses</title>
			<description>Background:
18F-FLT is a novel PET radiotracer which has demonstrated a strong potential utility for imaging cellular proliferation in human tumors in vivo. To facilitate future regulatory approval of 18F-FLT for clinical use, we wished to demonstrate the safety of radiotracer doses of 18F-FLT administered to human subjects, by: 1) performing an evaluation of the toxicity of 18F-FLT administered in radiotracer amounts for PET imaging, 2) comparing a radiotracer dose of FLT to clinical trial doses of FLT.
Methods:
Twenty patients gave consent to a 18F-FLT injection, subsequent PET imaging, and blood draws. For each patient, blood samples were collected at multiple times before and after 18F-FLT PET. These samples were assayed for a comprehensive metabolic panel, total bilirubin, complete blood and platelet counts. 18F-FLT doses of 2.59 MBq/Kg with a maximal dose of 185 MBq (5 mCi) were used. Blood time-activity curves were generated for each patient from dynamic PET data, providing a measure of the area under the FLT concentration curve for 12 hours (AUC12).
Results:
No side effects were reported. Only albumin, red blood cell count, hematocrit and hemoglobin showed a statistically significant decrease over time. These changes are attributed to IV hydration during PET imaging and to subsequent blood loss at surgery. The AUC12 values estimated from imaging data are not significantly different from those found from serial measures of FLT blood concentrations (p = 0.66). The blood samples-derived AUC12 values range from 0.232 ng*h/mL to 1.339 ng*h/mL with a mean of 0.802 &#177; 0.303 ng*h/mL. This corresponds to 0.46% to 2.68% of the lowest and least toxic clinical trial AUC12 of 50 ng*h/mL reported by Flexner et al (1994). This single injection also corresponds to a nearly 3,000-fold lower cumulative dose than in Flexner's twice daily trial.
Conclusion:
This study shows no evidence of toxicity or complications attributable to 18F-FLT injected intravenously.</description>
			<link>http://www.biomedcentral.com/1756-6649/7/3</link>
			
			 	<dc:creator>Eric Turcotte, Linda W Wiens, John R Grierson, Lanell M Peterson, Mark H Wener and Hubert Vesselle</dc:creator>
			
			<dc:source>BMC Medical Physics 2007, 7:3</dc:source>
			<dc:date>2007-07-03</dc:date>
			<dc:identifier>doi:10.1186/1471-2385-7-3</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-07-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1756-6649/7/2">
            
            <title>Comparison of manual and semi-automated delineation of regions of interest for radioligand PET imaging analysis</title>
			<description>Background:
As imaging centers produce higher resolution research scans, the number of man-hours required to process regional data has become a major concern. Comparison of automated vs. manual methodology has not been reported for functional imaging. We explored validation of using automation to delineate regions of interest on positron emission tomography (PET) scans. The purpose of this study was to ascertain improvements in image processing time and reproducibility of a semi-automated brain region extraction (SABRE) method over manual delineation of regions of interest (ROIs).
Methods:
We compared 2 sets of partial volume corrected serotonin 1a receptor binding potentials (BPs) resulting from manual vs. semi-automated methods. BPs were obtained from subjects meeting consensus criteria for frontotemporal degeneration and from age- and gender-matched healthy controls. Two trained raters provided each set of data to conduct comparisons of inter-rater mean image processing time, rank order of BPs for 9 PET scans, intra- and inter-rater intraclass correlation coefficients (ICC), repeatability coefficients (RC), percentages of the average parameter value (RM%), and effect sizes of either method.
Results:
SABRE saved approximately 3 hours of processing time per PET subject over manual delineation (p &lt; .001). Quality of the SABRE BP results was preserved relative to the rank order of subjects by manual methods. Intra- and inter-rater ICC were high (>0.8) for both methods. RC and RM% were lower for the manual method across all ROIs, indicating less intra-rater variance across PET subjects' BPs.
Conclusion:
SABRE demonstrated significant time savings and no significant difference in reproducibility over manual methods, justifying the use of SABRE in serotonin 1a receptor radioligand PET imaging analysis. This implies that semi-automated ROI delineation is a valid methodology for future PET imaging analysis.</description>
			<link>http://www.biomedcentral.com/1756-6649/7/2</link>
			
			 	<dc:creator>Tiffany W Chow, Shinichiro Takeshita, Kie Honjo, Christina E Pataky, Peggy L St Jacques, Maggie L Kusano, Curtis B Caldwell, Joel Ramirez, Sandra Black and Nicolaas PLG Verhoeff</dc:creator>
			
			<dc:source>BMC Medical Physics 2007, 7:2</dc:source>
			<dc:date>2007-01-29</dc:date>
			<dc:identifier>doi:10.1186/1471-2385-7-2</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-01-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1756-6649/7/1">
            
            <title>Variation in heart rate influences the assessment of transient ischemic dilation in myocardial perfusion scintigraphy</title>
			<description>Background:
Transient arrhythmias can affect transient ischemic dilation (TID) ratios. This study was initiated to evaluate the frequency and effect of normal heart rate change on TID measures in routine clinical practice.
Methods:
Consecutive patients undergoing stress/rest sestamibi gated myocardial perfusion scintigraphy were studied (N = 407). Heart rate at the time of stress and rest imaging were recorded. TID ratios were analyzed in relation to absolute change in heart rate (stress minus rest) for subjects with normal perfusion and systolic function (Group 1, N = 169) and those with abnormalities in perfusion and/or function (Group 2, N = 238).
Results:
In Group 1, mean TID ratio was inversely correlated with the change in heart rate (r = -0.47, P &lt; 0.0001). For every increase of 10 BPM in heart rate change, the TID ratio decreased by approximately 0.06 (95% confidence interval 0.04&#8211;0.07). In Group 2, multiple linear regression demonstrated that the change in heart rate (beta = -0.25, P &lt; 0.0001) and the summed difference score (beta = 0.36, P &lt; 0.0001) were independent predictors of the TID ratio.
Conclusion:
Normal variation in heart rate between the stress and rest components of myocardial perfusion scans is common and can influence TID ratios in patients with normal and abnormal cardiac scans.</description>
			<link>http://www.biomedcentral.com/1756-6649/7/1</link>
			
			 	<dc:creator>William D Leslie, Daniel P Levin and Sandor J Demeter</dc:creator>
			
			<dc:source>BMC Medical Physics 2007, 7:1</dc:source>
			<dc:date>2007-01-11</dc:date>
			<dc:identifier>doi:10.1186/1471-2385-7-1</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-01-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1756-6649/6/5">
            
            <title>Comparison of 18F SPECT with PET in myocardial imaging: A realistic thorax-cardiac phantom study</title>
			<description>Background:
Positron emission tomography (PET) imaging with fluorine-18 (18F) Fluorodeoxyglucose (FDG) and flow tracer such as Rubidium-82 (82Rb) is an established method for evaluating an ischemic but viable myocardium. However, the high cost of PET imaging restricts its wider clinical use. Therefore, less expensive 18F FDG single photon emission computed tomography (SPECT) imaging has been considered as an alternative to 18F FDG PET imaging. The purpose of the work is to compare SPECT with PET in myocardial perfusion/viability imaging.
Methods:
A nonuniform RH-2 thorax-heart phantom was used in the SPECT and PET acquisitions. Three inserts, 3 cm, 2 cm and 1 cm in diameter, were placed in the left ventricular (LV) wall to simulate infarcts. The phantom acquisition was performed sequentially with 7.4 MBq of 18F and 22.2 MBq of Technetium-99m (99mTc) in the SPECT study and with 7.4 MBq of 18F and 370 MBq of 82Rb in the PET study. SPECT and PET data were processed using standard reconstruction software provided by vendors. Circumferential profiles of the short-axis slices, the contrast and viability of the inserts were used to evaluate the SPECT and PET images.
Results:
The contrast for 3 cm, 2 cm and 1 cm inserts were for 18F PET data, 1.0 &#177; 0.01, 0.67 &#177; 0.02 and 0.25 &#177; 0.01, respectively. For 82Rb PET data, the corresponding contrast values were 0.61 &#177; 0.02, 0.37 &#177; 0.02 and 0.19 &#177; 0.01, respectively. For 18F SPECT the contrast values were, 0.31 &#177; 0.03 and 0.20 &#177; 0.05 for 3 cm and 2 cm inserts, respectively. For 99mTc SPECT the contrast values were, 0.63 &#177; 0.04 and 0.24 &#177; 0.05 for 3 cm and 2 cm inserts respectively. In SPECT, the 1 cm insert was not detectable. In the SPECT study, all three inserts were falsely diagnosed as "viable", while in the PET study, only the 1 cm insert was diagnosed falsely "viable".
Conclusion:
For smaller defects the 99mTc/18F SPECT imaging cannot entirely replace the more expensive 82Rb/18F PET for myocardial perfusion/viability imaging, due to poorer image spatial resolution and poorer defect contrast.</description>
			<link>http://www.biomedcentral.com/1756-6649/6/5</link>
			
			 	<dc:creator>Karin Kne&#353;aurek and Josef Machac</dc:creator>
			
			<dc:source>BMC Medical Physics 2006, 6:5</dc:source>
			<dc:date>2006-10-31</dc:date>
			<dc:identifier>doi:10.1186/1471-2385-6-5</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2006-10-31</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1756-6649/6/4">
            
            <title>A statistical investigation of normal regional intra-subject heterogeneity of brain metabolism and perfusion by F-18 FDG and O-15 H2O PET imaging</title>
			<description>Background:
The definite evaluation of the regional cerebral heterogeneity using perfusion and metabolism by a single modality of PET imaging has not been well addressed. Thus a statistical analysis of voxel variables from identical brain regions on metabolic and perfusion PET images was carried out to determine characteristics of the regional heterogeneity of F-18 FDG and O-15 H2O cerebral uptake in normal subjects.
Methods:
Fourteen normal subjects with normal CT and/or MRI and physical examination including MMSE were scanned by both F-18 FDG and O-15 H2O PET within same day with head-holder and facemask. The images were co-registered and each individual voxel counts (Q) were normalized by the gloabl maximal voxel counts (M) as R = Q/M. The voxel counts were also converted to z-score map by z = (Q - mean)/SD. Twelve pairs of ROIs (24 total) were systematically placed on the z-score map at cortical locations 15-degree apart and identically for metabolism and perfusion. Inter- and intra-subject correlation coefficients (r) were computed, both globally and hemispherically, from metabolism and perfusion: between regions for the same tracer and between tracers for the same region. Moments of means and histograms were computed globally along with asymmetric indices as their hemispherical differences.
Results:
Statistical investigations verified with data showed that, for a given scan, correlation analyses are expectedly alike regardless of variables (Q, R, z) used. The varieties of correlation (r's) of normal subjects, showing symmetry, were mostly around 0.8 and with coefficient of variations near 10%. Analyses of histograms showed non-Gaussian behavior (skew = -0.3 and kurtosis = 0.4) of metabolism on average, in contrast to near Gaussian perfusion.
Conclusion:
The co-registered cerebral metabolism and perfusion z maps demonstrated regional heterogeneity but with attractively low coefficient of variations in the correlation markers.</description>
			<link>http://www.biomedcentral.com/1756-6649/6/4</link>
			
			 	<dc:creator>Ching-yee Oliver Wong, Joseph Thie, Marianne Gaskill, Richard Ponto, Jack Hill, Hai-yan Tian, Helena Balon, Dafang Wu, Darlene Fink-Bennett and Conrad Nagle</dc:creator>
			
			<dc:source>BMC Medical Physics 2006, 6:4</dc:source>
			<dc:date>2006-07-12</dc:date>
			<dc:identifier>doi:10.1186/1471-2385-6-4</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Physics</prism:publicationName>
					
			
							
					<prism:issn>1756-6649</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2006-07-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
